Brief: Akoustis Technologies Q4 Basic EPS USD -0.25
06/09/2023 12:05
Sep 06 (Reuters) - Akoustis Technologies Q4 revenue USD 8.333 million vs. IBES estimate USD 8.44 million. * Q4 operating income USD -17.929 million * Q4 net income USD -17.765 million * Q4 pretax profit USD -17.794 million * Q4 gross profit USD -1.704 million * Q4 operating expenses USD 16.224 million
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut